David Cooper (immunologist)

David Albert Cooper (19 April 1949 – 18 March 2018) was an Australian HIV/AIDS researcher, immunologist, professor at the University of New South Wales, and the director of the Kirby Institute. He and Professor Ron Penny diagnosed the first case of HIV in Australia. Provided by Wikipedia
Showing 1 - 20 results of 36 for search 'David A. Cooper', query time: 0.11s Refine Results
  1. 1
    In memoriam: Joep Lange MD, PhD

    In memoriam: Joep Lange MD, PhD by Chris Beyrer, Stefano Vella, David A. Cooper

    Published 2014-01-01
    Get full text
    Article
  2. 2
    Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.

    Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action. by James B Gilmore, Anthony D Kelleher, David A Cooper, John M Murray

    Published 2013-01-01
    Get full text
    Article
  3. 3
    HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

    HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. by Hila Haskelberg, Damien V Cordery, Janaki Amin, Anthony D Kelleher, David A Cooper, Sean Emery, STEAL Study Group

    Published 2014-01-01
    Get full text
    Article
  4. 4
    Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

    Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. by Allison Martin, Janaki Amin, Sean Emery, David Baker, Andrew Carr, David A Cooper, Mark Bloch, STEAL Study Group

    Published 2011-01-01
    Get full text
    Article
  5. 5
    Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

    Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial. by Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper

    Published 2014-01-01
    Get full text
    Article
  6. 6
    Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing

    Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing by Chantelle Ahlenstiel, Catalina Mendez, Steven T H Lim, Katherine Marks, Stuart Turville, David A Cooper, Anthony D Kelleher, Kazuo Suzuki

    Published 2015-01-01
    Get full text
    Article
  7. 7
    The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

    The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa. by Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P Wilson, Sean Emery, David A Cooper, Mark A Boyd

    Published 2013-01-01
    Get full text
    Article
  8. 8
    HIV dynamics linked to memory CD4+ T cell homeostasis.

    HIV dynamics linked to memory CD4+ T cell homeostasis. by John M Murray, John Zaunders, Sean Emery, David A Cooper, William J Hey-Nguyen, Kersten K Koelsch, Anthony D Kelleher

    Published 2017-01-01
    Get full text
    Article
  9. 9
    Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

    Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. by Alexander Hoare, Stephen J Kerr, Kiat Ruxrungtham, Jintanat Ananworanich, Matthew G Law, David A Cooper, Praphan Phanuphak, David P Wilson

    Published 2010-06-01
    Get full text
    Article
  10. 10
    Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES).

    Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLE... by Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J Templeton, David Baker, Michelle Giles, Matthew G Law, David A Cooper

    Published 2017-01-01
    Get full text
    Article
  11. 11
    Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

    Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. by Yu Ming Paul Lam, Kristin L McBride, Janaki Amin, Damien V Cordery, Anthony D Kelleher, David A Cooper, Kersten K Koelsch

    Published 2012-01-01
    Get full text
    Article
  12. 12
    Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing

    Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing by Kazuo Suzuki, Shinichiro Hattori, Katherine Marks, Chantelle Ahlenstiel, Yosuke Maeda, Takaomi Ishida, Michelle Millington, Maureen Boyd, Geoff Symonds, David A Cooper, Seiji Okada, Anthony D Kelleher

    Published 2013-01-01
    Get full text
    Article
  13. 13
    Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.

    Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. by Alan Winston, Rebekah Puls, Stephen J Kerr, Chris Duncombe, Patrick Li, John M Gill, Reshmie Ramautarsing, Simon D Taylor-Robinson, Sean Emery, David A Cooper, ALTAIR Study Group

    Published 2015-01-01
    Get full text
    Article
  14. 14
    Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

    Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomi... by David A Cooper, Damien V Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L de Andrade Neto, Joseph Scherer, Ricardo L Chaves, Patrick Robinson, study team

    Published 2016-01-01
    Get full text
    Article
  15. 15
    Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.

    Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection. by Sarah C Sasson, John J Zaunders, Nabila Seddiki, Michelle Bailey, Kristin McBride, Kersten K Koelsch, Kate M Merlin, Don E Smith, David A Cooper, Anthony D Kelleher

    Published 2012-01-01
    Get full text
    Article
  16. 16
    Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

    Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency. by Denise C Hsu, Stephen J Kerr, Thatri Iampornsin, Sarah L Pett, Anchalee Avihingsanon, Parawee Thongpaeng, John J Zaunders, Sasiwimol Ubolyam, Jintanat Ananworanich, Anthony D Kelleher, David A Cooper

    Published 2013-01-01
    Get full text
    Article
  17. 17
    The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study.

    The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study. by Nan Phyu Sin Toe Myint, Ne Myo Aung, Myint Soe Win, Thu Ya Htut, Anna P Ralph, David A Cooper, Myo Lwin Nyein, Mar Mar Kyi, Josh Hanson

    Published 2018-01-01
    Get full text
    Article
  18. 18
    HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

    HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport

    Published 2015-07-01
    Get full text
    Article
  19. 19
    The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study

    The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study by Swe Swe Thit, Ne Myo Aung, Zaw Win Htet, Mark A. Boyd, Htin Aung Saw, Nicholas M. Anstey, Tint Tint Kyi, David A. Cooper, Mar Mar Kyi, Josh Hanson

    Published 2017-08-01
    Get full text
    Article
  20. 20
    Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

    Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission. by Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport

    Published 2016-08-01
    Get full text
    Article

Search Tools: